17-(7-羟基-6-甲基-庚烷-2-基)-10,13-二甲基-2,3,4,5,6,7,8,9,11,12,14,15,16,17-十四氢-1H-环戊烯并[a]菲-3,7,12-三醇 | 862-53-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 17-(7-羟基-6-甲基-庚烷-2-基)-10,13-二甲基-2,3,4,5,6,7,8,9,11,12,14,15,16,17-十四氢-1H-环戊烯并[a]菲-3,7,12-三醇
• 中文别名: 3-哒嗪甲酰胺,1,6-二氢-1-甲基-6-羰基-
• 英文名称: 27-deoxy-5β-cyprinol
• 英文别名: 5β-cholestane-3α,7α,12α,26-tetrol；26-OH-THC；5beta-Cholestane-3alpha,7alpha,12alpha,26-tetrol；(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-17-[(2R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7,12-triol
• CAS: 862-53-3
• 化学式: C₂₇H₄₈O₄
• 分子量: 436.676
• InChiKey: XJZGNVBLVFOSKJ-XZULNKEGSA-N

物化性质

• 熔点：
  232 °C
• 沸点：
  572.6±50.0 °C(Predicted)
• 密度：
  1.098±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  80.9
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• Mitochondrial P450
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：EP0477961A2

  公开（公告）日：1992-04-01

  The expression of mitochondrial P450 in yeast is disclosed. The mitochondrial P450 includes a chimeric P450 in which a signal sequence present at the N-terminus of a mammalian mitochondrial P450 has been substituted by a signal of a yeast mitochondrial protein and a chimeric P450 in which the latter signal has been further substituted by a targeting signal sequence to microsome. An expression plasmid for producing the enzyme in a large scale, a recombinant yeast strain carrying the expression plasmid, a process for producing the enzyme by the use of the recombinant yeast, and a process for producing 5β-cholestane-3α, 7α, 12α, 27-tetrol, 25-hydroxyvitamin D₃ and 1α,25-dihydroxyvitamin D₃ are also disclosed.

  本发明公开了在酵母中表达线粒体 P450 的方法。线粒体 P450 包括一种嵌合 P450，其中哺乳动物线粒体 P450 N 端的信号序列被酵母线粒体蛋白的信号所取代；还包括一种嵌合 P450，其中后一信号进一步被微粒体的靶向信号序列所取代。 本发明还公开了一种大规模生产该酶的表达质粒、一种携带该表达质粒的重组酵母菌株、一种利用该重组酵母生产该酶的工艺，以及一种生产 5β-胆甾烷-3α、7α、12α、27-四醇、25-羟基维生素 D₃和 1α,25-二羟基维生素 D₃的工艺。
• Implants for localized drug delivery and methods of use thereof
  申请人：The Regents of the University of California

  公开号：US10912933B2

  公开（公告）日：2021-02-09

  Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to a hydrophobic active agent, and a silicone tubing having a wall permeable to the active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein the two ends of the silicone tubing extend from the first surface, and wherein a path outlined by a second length of the tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver a hydrophobic active agent to a target tissue, and kits that find use in performing the present method.

  本文提供了一种向目标组织输送疏水活性剂的植入物。该植入物可包括界定第一表面和与第一表面相对的第二表面的支架，其中支架基本上不渗透疏水活性剂，以及具有可渗透活性剂壁的硅胶管，其中硅胶管的第一长度贴在支架的第一表面上，其中硅胶管的两端从第一表面延伸，并且第一长度内的第二长度的硅胶管所勾勒的路径是迂回的。此外，还提供了一种使用植入物向目标组织局部递送疏水活性剂的方法，以及可用于实施本方法的试剂盒。
• COATINGS FOR IMPLANTABLE MEDICAL DEVICES FOR LIPOSOME DELIVERY
  申请人：Miv Therapeutics Inc.

  公开号：EP2136856A1

  公开（公告）日：2009-12-30
• IMPLANTS FOR LOCALIZED DRUG DELIVERY AND METHODS OF USE THEREOF
  申请人：The Regents of the University of California

  公开号：EP3183026B1

  公开（公告）日：2019-10-30
• Implants for Localized Drug Delivery and Methods of Use Thereof
  申请人：KIRIAKIS Jim

  公开号：US20170224970A1

  公开（公告）日：2017-08-10

  Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to a hydrophobic active agent, and a silicone tubing having a wall permeable to the active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein the two ends of the silicone tubing extend from the first surface and wherein a path outlined by a second length of the tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver a hydrophobic active agent to a target tissue, and kits that find use in performing the present method.